Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials

Clinical Pharmacokinetics

Volumn 55, Issue 1, 2016, Pages 121-130

  Minocha, Mukul ^a   Tran, Jonathan Q ^b   Sheridan, James P ^a   Othman, Ahmed A ^a,c  

^a ABBVIE INC   (United States)

^b BIOGEN   (United States)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; PLACEBO; IL2RA PROTEIN, HUMAN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; IC50; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONLINEAR SYSTEM;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RECEPTORS, INTERLEUKIN-2;

EID: 84954388777     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0305-z     Document Type: Article

References (24)

1. Malek TR. The biology of interleukin-2. Ann Rev Immunol. 2008;26:453–79.
2. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13–25.
3. Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56 (bright) NK cells. J Immunol. 2010;185(2):1311–20.
4. Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56 (bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler. 2011;17(12):1441–8.
5. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10(1):55–67.
6. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31.
7. Wiendl H, Gross CC. Modulation of IL-2R alpha with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9(7):394–404.
8. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009;41(9):1011–5.
9. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353–60.
10. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007;27(1):1–18.
11. Roche HL. Zenapax label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf. Accessed 7 July 2015.
12. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338(3):161–5.
13. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009;66(4):483–9.
14. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56(6):864–7.
15. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9(4):381–90.
16. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167–75.
17. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103(15):5941–6.
18. Selmaj K. Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study. Mult Scler J. 2014;20(S1):67–284.
19. Kappos L. Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. interferon β-1a in RRMS patients. Mult Scler J. 2014;20(S1):14–66.
20. Othman AA, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014;53(10):907–18.
21. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol. 1992;32:185–209.
22. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakraverty R, et al. The number of human peripheral blood CD4+ CD25 high regulatory T cells increases with age. Clin Exp Immunol. 2005;140(3):540–6.
23. Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G, Hildeman DA, et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol. 2008;181(3):1835–48.
24. Hampras SS, Nesline M, Wallace PK, Odunsi K, Furlani N, Davis W, et al. Predictors of immunosuppressive regulatory T lymphocytes in healthy women. J Cancer Epidemiol. 2012;2012:191090.